Live feed16:05:00·1030dPRReleasevia QuantisnowTerns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASHByQuantisnow·Wall Street's wire, on your screen.TERN· Terns Pharmaceuticals Inc.Health Care
